Since the earliest recorded attempts at hip replacement surgery more than 100 years ago ([@bib14]), millions of patients have undergone total hip arthroplasty (THA) worldwide ([@bib22]). A variety of materials have been used for the bearing surfaces of hip prostheses, the principal modern options being metal-on-polyethylene, metal-on-metal, ceramic-on-polyethylene, and ceramic-on-ceramic. Systemic exposure to chromium, cobalt, nickel, and aluminium alloys can occur because of the formation of metal wear nanoparticles that are released both from metal-on-metal and metal-on-polyethylene bearings, resulting in a postoperative increase in metal ion levels at different organ sites, especially those comprising the lymphoreticular system. These particles circulate locally and systemically, penetrate cell plasma membranes, bind to cellular proteins and enzymes, cause chromosome aberrations and DNA damage, modulate cytokine expression, and might, therefore, cause long-term increased risks of cancer ([@bib35]; [@bib15]; [@bib22]). Although a Working Group established by the International Agency for Research on Cancer concluded that there is inadequate evidence in humans for the carcinogenicity of metallic implants, metallic foreign bodies, and orthopaedic implants of complex composition ([@bib11]), this finding does not rule out a risk of cancer entirely, and the evidence reviewed pre-dated the emergence of the modern generation of metal-on-metal hip prostheses ([@bib4]).

Two early cohort studies of cancer risk following THA found an increased risk of lymphohaematopoietic malignancies ([@bib7]; [@bib31]), but apart from an excess of multiple myeloma emerging during long-term follow-up ([@bib27]), other studies ([@bib16]; [@bib17]; [@bib8]; [@bib32], [@bib35]; [@bib19]; [@bib21]; [@bib10]; [@bib15]) have not shown an excess risk of these cancers. However, some other studies have reported excess risks of melanoma of the skin ([@bib17]; [@bib19]; [@bib27]; [@bib15]), prostate cancer ([@bib17]; [@bib27]), kidney cancer ([@bib17]), and basal cell carcinoma of the skin, specifically in patients with modern generation metal-on-metal hip replacements ([@bib15]). Although there have been case reports of bone and soft tissue sarcomas arising adjacent to orthopaedic implants ([@bib11]; [@bib30]), none of the cohort studies so far conducted have demonstrated a statistically significant excess risk of these kinds of cancers. Recent meta-analyses and reviews of studies of cancer risk following THA (as well as, in some cases, total knee arthroplasty) have also identified increased risks of skin melanoma ([@bib33], [@bib34]; [@bib20]), prostate cancer ([@bib33], [@bib34]; [@bib20]), cancer of the endometrium ([@bib33]), and cancers of the urinary tract and mouth/pharynx ([@bib20]). More recently, a record linkage study between the National Joint Registry of England and hospital episode statistics did not find any evidence of an association between metal-on-metal hip replacements and increased risk of admission to hospital with cancer in the first 7 years after hip replacement ([@bib28]).

Recent concerns and publicity about a possible association between the new generation of metal-on-metal hip joint replacement devices and subsequent risk of cancer prompted us to investigate the risk of cancer among patients treated with THA or primary resurfacing arthroplasty of the hip in Scotland (estimated total mid-year population approximately 5.25 million in 2011).

Materials and Methods
=====================

Study population
----------------

The study population was drawn from the permanently linked database of acute hospital discharges, cancer registrations, and mortality records in Scotland ([@bib13]). From National Health Service (NHS) acute hospital discharge records, we selected patients undergoing primary total hip replacement or primary resurfacing arthroplasty of the hip during the period 1990--2009 inclusive, based on the following OPCS-4 procedure codes ([@bib18]): W37.1: Primary total prosthetic replacement of hip joint using cement.W38.1: Primary total prosthetic replacement of hip joint not using cement.W39.1: Primary total prosthetic replacement of hip joint NEC.W58.1+Z84.3: Primary resurfacing arthroplasty of joint+hip joint.

These OPCS-4 codes include, but are not specific to, metal-on-metal hip replacements, which, in common with the rest of the world, increased in use in Scotland between 2005 and 2009. For example, it is not possible to distinguish large diameter head metal-on-metal total hip replacements.

Each member of the study cohort was followed up for cancer incidence from the date of their earliest relevant hip surgery until death or the end of 2010 (whichever occurred first). As in other recent studies ([@bib35]; [@bib15]), follow-up was not censored at the date of diagnosis of first cancer; all primary cancers diagnosed during the follow-up period were counted as observed cases. Cancers occurring before each patient\'s hip operation were disregarded.

Statistical methods
-------------------

Indirectly standardised incidence ratios (SIRs) were calculated for selected cancers based on the ratio of observed to expected numbers of cancers. The list of cancers investigated ([Appendix 1](#app1){ref-type="app"}) was determined before analysis, and was based on excess risks of specific cancers reported from previous studies, as well as a list of cancers identified in an unpublished study from Wales, which had been a source of concern. Expected numbers of cancers were calculated by applying national age-, sex-, deprivation category-, and calendar period-specific (and cancer-specific) rates to the age-, sex-, deprivation category-, and calendar period-specific person-years at risk (PYAR) in the study cohort. Rates were calculated using population denominator data sourced from the General Register Office for Scotland (now part of National Records of Scotland). The Scottish Index of Multiple Deprivation (SIMD) 2004 ([@bib24]) was used as a postcode-referenced, small area indicator of socioeconomic position. This has seven domains (income, employment, education, housing, health, crime, and geographical access) at 'datazone\' level (areas with approximately 500--1000 household residents), which have been combined into an overall index to identify area concentrations of multiple deprivation. SIMD population estimates are only available from 1996 onwards, so we used 1996 estimates for the period 1990--1995. We calculated 95% confidence intervals (CIs) for SIRs by assuming that the observed numbers of cancers follow a Poisson distribution. SIRs with 95% CIs that did not include the value 1.00 were regarded as statistically significant. SIRs were calculated for the total period of observation, and also partitioned by a period of hip surgery (1990--1994, 1995--1999, 2000--2004, and 2005--2009), and by time since hip operation (\<1 year, 1--4 years, 5--9 years, and ⩾10 years). In addition, we performed a subgroup analysis of patients recorded as undergoing primary resurfacing arthroplasty during 2000--2009.

Results
=======

The distribution and characteristics of the study population are summarised in [Table 1](#tbl1){ref-type="table"}. Overall, the study cohort included 71 990 patients yielding 547 001 PYAR. The female-to-male ratio was 1.6:1.0, and almost 80% of patients were aged 60 years or older at the time of their first relevant hip surgery. Higher proportions of patients were from the second and third least deprived fifths of SIMD 2004, whereas lower proportions were from the least and (especially) the most deprived fifth. The overwhelming majority of patients (\>98% in both sexes combined) were recorded as having primary total hip replacement rather than primary resurfacing arthroplasty as their first relevant procedure. More than 99% (1317 out of 1325) of primary resurfacing arthroplasties were performed during 2000--2009. In both sexes combined, the mean age at study entry was 68 years and the mean number of years of follow-up was 7.6. During follow-up, 13 946 cancers were diagnosed in the whole study cohort and the mean age at diagnosis of cancer was 76.1 years.

[Table 2](#tbl2){ref-type="table"} shows the observed numbers of cancers, SIRs, and 95% CIs, by calendar period of hip operation. Standardised incidence ratios were significantly higher than expected for cutaneous melanoma and for basal cell carcinoma of the skin among patients operated on during 2005--2009 (SIR: 1.42; 95% CI: 1.07--1.86 and SIR: 1.12; 95% 1.01--1.24, respectively); for prostate cancer among patients operated on during 1990--2009 (SIR: 1.07; 95% CI: 1.01--1.14); for multiple myeloma and other immunoproliferative neoplasms among patients operated on during 1995--1999 (SIR: 1.43; 95% CI: 1.13--1.80) and 1990--2009 (SIR: 1.22; 95% CI: 1.06--1.41); and for all cancers combined among patients operated on during 1995--1999 (SIR: 1.07; 95% CI: 1.04--1.10), 2000--2004 (SIR: 1.04; 95% CI: 1.00--1.08), 2005--2009 (SIR: 1.13; 95% CI: 1.09--1.18), and 1990--2009 (SIR: 1.05; 95% CI: 1.04--1.07). Significantly low SIRs were observed for lung cancer during every calendar period and for cancers of the upper gastrointestinal tract and bladder during the whole study period combined.

[Table 3](#tbl3){ref-type="table"} shows the observed numbers of cancers, SIRs, and 95% CIs, by time since hip operation. A significant excess of basal cell carcinoma of the skin (SIR: 1.11; 95% CI: 1.04--1.18), multiple myeloma and other immunoproliferative neoplasms (SIR: 1.37; 95% CI: 1.09--1.70), and all cancers combined (SIR: 1.10; 95% CI: 1.07--1.13) occurred during the interval 1--4 years following primary hip surgery. Significantly low SIRs were observed for lung cancer during every follow-up interval, for cancers of the oesophagus during the interval 5--9 years after surgery, and for bladder cancer within a year of surgery or 10 years or more after surgery.

In the subgroup analysis of 1317 patients recorded as undergoing primary resurfacing arthroplasty between 2000 and 2009, during 5698 PYAR, 39 cancers were observed (SIR: 1.23; 95% CI: 0.87--1.68). These included 10 prostate cancers (SIR: 1.89; 95% CI: 0.90--3.50), six basal cell carcinomas of the skin (SIR: 0.62; 95% CI: 0.22--1.36), one cutaneous melanoma (SIR: 0.62; 95% CI: 0.00--3.56), and no myelomas. Between zero and two cases were observed for remaining cancer sites/types, and no SIRs were significantly different from 1.00 in this subgroup of patients.

Discussion
==========

Although our results imply an overall excess risk of cancer of 5% (SIR: 1.05) associated with prior hip arthroplasty, this seems unlikely to be of aetiological or clinical significance. Standardised incidence ratios of a similar order of magnitude (although not quite statistically significant) have been reported previously from a Swedish study (SIR: 1.03; 95% CI: 1.00--1.06) and for a non-metal-on-metal hip replacement cohort from Finland (SIR: 1.04; 95% CI: 0.99--1.09) ([@bib17]; [@bib15]). However, the majority of studies have reported lower than expected risks of cancer overall following hip replacement surgery ([@bib19]; [@bib21]; [@bib33], [@bib35]; [@bib20]; [@bib28]). It has been speculated that this may reflect a 'healthy patient effect\' since patients have to have a certain level of fitness to tolerate major surgery ([@bib21]; [@bib15]; [@bib28]). It might equally reflect higher than average lifetime levels of physical activity (and therefore injury) among some patients presenting with osteoarthritis of the hip, which would tend to reduce the risk of certain cancers ([@bib36]). Alternatively, it could reflect the use of medication, such as non-steroidal anti-inflammatory agents, which may also reduce the risk of some cancers ([@bib19]; [@bib21]).

It is important to note that our study population was not evenly distributed across the deprivation fifths, with a much lower proportion than expected in the most deprived fifth ([Table 1](#tbl1){ref-type="table"}). Although our efforts to standardise our results for socioeconomic position may have succeeded in attenuating any 'healthy patient effect\', it must be acknowledged that our use of the SIMD 2004 indicator ([@bib24]), based on the area of residence and imperfect population estimates (see Materials and Methods), is very unlikely to have eliminated all confounding related to this factor. As noted above, it is probable that recipients of hip replacements also differ systematically from the general population in other respects, such as lifestyle factors and medication history, which may determine their risk of developing cancer. We have not been able to make any adjustment for these factors, which may represent additional sources of confounding.

Some previous studies have excluded patients with rheumatoid arthritis at baseline on the grounds that they have a non-typical pattern of cancer ([@bib32], [@bib35]; [@bib19]; [@bib21]; [@bib15]). We did not feel that this was appropriate in our study because a previous study of hospitalised patients with rheumatic diseases in Scotland suggested even more atypical patterns of cancer risk among patients with osteoarthritis: SIRs for all cancers (excluding non-melanoma skin cancer) in patients with rheumatoid arthritis were 1.11 (95% CI: 1.03--1.21) in male patients and 0.96 (95% CI: 0.90--1.01) in female patients; and in patients with osteoarthritis 0.85 (95% CI: 0.81--0.88) in male patients and 0.83 (95% CI: 0.80--0.86) in female patients ([@bib29]). The proportion of patients with rheumatoid arthritis (when this has been reported) in previous cohorts of hip replacement patients has typically been low. For example, in a previous study including Scottish patients, only 12% of the THA cohort had a main diagnosis of rheumatoid arthritis, and adjustment for this in a statistical model did not change the relative risk of leukaemia/lymphoma significantly ([@bib8]).

Theoretically, using hospital discharge records, it would also be possible to allow for co-morbid conditions recorded during hospitalisation that have been associated with altered risks of cancer, such as diabetes mellitus ([@bib9]). However, we did not attempt this because, in Scotland at least, there is some evidence of under-recording of comorbid conditions in hospital discharge data ([@bib1]).

The consistent finding of a lower risk of lung cancer in our cohort has been reported in previous studies ([@bib16]; [@bib32], [@bib33], [@bib35]; [@bib21]; [@bib10]; [@bib20]; [@bib15]) and may reflect a lower prevalence of smoking among patients regarded as fit for surgery, or that patients with a history of smoking have been advised to give up before surgery. At the same time, however, there is some evidence that the risk of severe osteoarthritis of the hip may be lower in smokers, at least as far as men are concerned ([@bib35]). These potential explanations might also account for the deficits we observed in other smoking-related cancers (upper gastrointestinal tract and bladder).

Some other studies have reported excess risks of melanoma of the skin ([@bib17]; [@bib19]; [@bib27]; [@bib33], [@bib34]; [@bib20]; [@bib15]), basal cell carcinoma of the skin (specifically in patients with modern generation metal-on-metal hip replacements) ([@bib15]), and prostate cancer ([@bib17]; [@bib27]). Although the recent UK study ([@bib28]) had the major advantage of being able to focus on metal-on-metal hip replacements by using the National Joint Registry of England to ascertain exposure, their assessment of outcome was based on linkage to hospital episode statistics, which are subject to less quality assurance than cancer registry data, and are likely to be missing information on some cancers, such as cutaneous melanoma, that do not necessarily lead to hospital admission. It has been speculated that the excess risk of melanoma reported in several studies could be due to surveillance bias ([@bib19]), although we did not observe a significantly increased risk during earlier follow-up intervals. All major types of skin cancer ([@bib6]) and prostate cancer ([@bib26]) are considerably more common among more affluent individuals, so the increased risks of these cancers observed in our study could reflect residual confounding by socioeconomic position. However, in contrast to the recent Finnish study of patients with modern generation metal-on-metal hip replacements ([@bib15]), our subgroup analysis of patients undergoing primary resurfacing arthroplasty (although based on relatively small numbers) did not show an increased risk of basal cell carcinoma of the skin.

An increased risk of multiple myeloma has been reported in one previous study ([@bib27]), but this only emerged during long-term follow-up (⩾15 years), which is not really consistent with our findings, and was of borderline statistical significance (SIR 1.86; 95% CI: 1.01--3.11). Like skin cancer, myeloma may also be susceptible to surveillance bias, related to routine blood testing and X-rays in patients with rheumatic conditions, especially those undergoing surgery. Modestly elevated risks of myeloma have been reported in some (but not all) studies of patients with rheumatoid arthritis as well as some other autoimmune diseases and chronic inflammatory conditions, and some studies have found positive but nonsignificant associations between use of anti-inflammatory medications and myeloma ([@bib5]). However, none of these associations are entirely consistent or convincing. The majority of studies ([@bib17]; [@bib32], [@bib33], [@bib34], [@bib35]; [@bib19]; [@bib21]; [@bib10]; [@bib20]; [@bib15]) have not shown an increased risk of this malignancy following hip replacement surgery.

Our study has a number of strengths. Hospitalisation data are supported by an active programme of quality assurance including regular assessments of data quality. In relation to discharges from acute hospitals, the accuracy of coding of main operation/procedure has been estimated to be around 94% overall and has been relatively stable for around 20 years ([@bib12]). In particular, the coding of arthroplasty procedures is quality assured in the context of the [@bib23], which was established in 1999. Scottish Cancer Registry data have also been shown to be of comparatively high quality ([@bib2], [@bib3]), and record linkage in Scotland is believed to be highly accurate and complete ([@bib13]).

The main weakness of our study is that, in the absence of a joint register in Scotland, we were unable to assess the risk of cancer separately for all metal-on-metal arthroplasties. Thus, we have only been able to infer the predominant types of prostheses in use based on the era of surgery and local specialist knowledge. Over 4000 patients in receipt of modern generation metal-on-metal prostheses have been identified in a survey of NHS Boards in Scotland ([@bib25]). However, this represents a relatively small proportion of all patients undergoing hip arthroplasty, and suggests that Scottish orthopaedic surgeons may not have adopted these new generation prostheses with the same enthusiasm as some of their peers in other countries.

Patients who had their hip surgery in the private sector, not funded by the NHS, are unlikely to be included in acute NHS hospital discharge data, although in Scotland, it is estimated that the majority (well over 90%) of these procedures are carried out in, or at least funded by, the NHS. Although the linked database in Scotland extends back to 1981, procedure coding is less precise and may have been less accurate in the 1980s. For this reason, we restricted our study to patients operated on from 1990 onwards, meaning that long-term follow-up is somewhat limited, especially for the cohort operated on most recently who are more likely to have received metal-on-metal prostheses. Although we were concerned that we might have overestimated risks by including cases diagnosed in the first year of follow-up, there is little evidence of surveillance bias in our results. Partitioning our analyses by cancer type, period of surgery, and interval of follow-up has inevitably resulted in multiple testing, which increases the risk of a type I error (rejection of a true null hypothesis). At the same time, however, we had limited statistical power to detect altered risks of cancer in our subgroup analysis of patients who had undergone primary resurfacing arthroplasty.

In conclusion, although we observed an increased risk of all cancers combined in our cohort, this was small in magnitude and could easily be the result of confounding. We found no statistically significant evidence of an increased risk of cancer after long-term (⩾10 years) follow-up, no evidence of increased risks in our subgroup analysis of patients who underwent primary resurfacing arthroplasty, and for specific types of cancer, no consistent pattern of increased risk across all calendar periods of surgery or intervals of follow-up. The accumulated body of research on this topic does not suggest a major cause for concern. However, follow-up of individuals operated on most recently, who are more likely to have been exposed to new-generation metal-on-metal prostheses, is necessarily limited and it will be important to re-assess the risk of cancer among this group after a further period of follow-up has accrued. Discussions are currently taking place about the feasibility of developing a joint replacement register in Scotland, which in future would provide the possibility of examining cancer risk by type of prosthesis, thereby addressing one of the main limitations of this study.
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###### Distribution and summary characteristics of the study population

                                                  **Males**   **Females**   **Persons**                  
  ---------------------------------------------- ----------- ------------- ------------- ------ -------- ------
  **Age group (years)**                                                                                  
  \<40                                               637          2.3           730       1.7     1367    1.9
  40--49                                            1469          5.3          1651       3.7     3120    4.3
  50--59                                            4960         17.8          5955       13.5   10 915   15.2
  60--69                                            9575         34.4         13 434      30.4   23 009   32.0
  70--79                                            8656         31.1         15 723      35.6   24 379   33.9
  ⩾80                                               2501          9.0          6699       15.2    9200    12.8
  **Deprivation fifth**                                                                                  
  1 -- Least deprived                               5277         19.0          8137       18.4   13 414   18.6
  2                                                 6474         23.3          9496       21.5   15 970   22.2
  3                                                 6566         23.6         10 118      22.9   16 684   23.2
  4                                                 5413         19.5          9178       20.8   14 591   20.3
  5 -- Most deprived                                4068         14.6          7263       16.4   11 331   15.7
  **Type of surgery**                                                                                    
  Primary total hip replacement                    26 909        96.8         43 756      99.0   70 665   98.2
  Primary resurfacing arthroplasty                   889          3.2           436       1.0     1325    1.8
  Total                                            27 798         100         44 192      100    71 990   100
  Mean age at study entry (years)                   66.3         69.1          68.0                      
  Median calendar year at study entry               2001         2001          2001                      
  Mean number of years of follow-up                  7.5          7.7           7.6                      
  Person-years at risk                             208 001      338 999       547 001                    
  Number of cancers diagnosed during follow-up      6253         7693         13 ,946                    
  Mean age at diagnosis of cancer                   75.2         76.7          76.1                      

###### Obs, SIRs[a](#t2-fn2){ref-type="fn"}, and 95% CI, by calendar period of hip operation

                                                    **Calendar period of hip operation**                                                                                                                                                                                         
  ------------------------------------------------ -------------------------------------- ---------- ---------- ---------- ------ ---------- ---------- ---------- ------ ---------- ---------- ---------- ------ ---------- ---------- ---------- ------- ---------- ---------- ----------
  Mouth, pharynx                                                     37                      0.82       0.58       1.14      44      0.86       0.63       1.16      36      0.93       0.65       1.29      21      0.84       0.52       1.29      138      0.86       0.73       1.02
  Oesophagus                                                         90                      0.89       0.71       1.09      89      0.84       0.68       1.04      56      0.78       0.59       1.01      42      1.00       0.72       1.35      277    **0.86**   **0.76**   **0.97**
  Stomach                                                           107                      0.86       0.71       1.04     108      0.92       0.76       1.11      58      0.80       0.61       1.03      31      0.78       0.53       1.10      304    **0.86**   **0.77**   **0.96**
  Lung                                                              475                    **0.80**   **0.73**   **0.88**   506    **0.82**   **0.75**   **0.89**   298    **0.69**   **0.62**   **0.78**   218    **0.85**   **0.74**   **0.97**   1497    **0.79**   **0.75**   **0.83**
  Bone                                                               3                       1.45       0.27       4.30      3       1.50       0.28       4.45      1       0.71       0.00       4.08      0       0.00       ---        ---        7       1.09       0.43       2.26
  Connective tissue                                                  14                      1.34       0.73       2.26      12      1.08       0.55       1.89      7       0.90       0.36       1.86      4       0.87       0.23       2.24      37       1.09       0.77       1.50
  Melanoma of skin                                                   70                      1.15       0.90       1.46      64      0.89       0.69       1.14      62      1.09       0.84       1.40      54    **1.42**   **1.07**   **1.86**    250      1.10       0.97       1.25
  Basal cell carcinoma of skin                                      637                      1.02       0.94       1.10     734      1.03       0.95       1.10     551      1.03       0.95       1.12     380    **1.12**   **1.01**   **1.24**   2302      1.04       1.00       1.08
  Corpus uteri                                                       48                      0.98       0.73       1.31      55      0.97       0.73       1.26      47      1.06       0.78       1.41      30      1.02       0.68       1.45      180      1.00       0.86       1.16
  Prostate                                                          317                      1.11       0.99       1.23     331      1.05       0.94       1.16     240      1.07       0.94       1.22     145      1.06       0.90       1.25     1033    **1.07**   **1.01**   **1.14**
  Bladder[b](#t2-fn3){ref-type="fn"}                                181                      0.89       0.77       1.03     184      0.85       0.73       0.99     124      0.84       0.70       1.00      78      0.89       0.70       1.11      567    **0.87**   **0.80**   **0.94**
  Kidney                                                             78                      1.10       0.87       1.37      82      1.05       0.83       1.30      65      1.12       0.86       1.42      31      0.84       0.57       1.19      256      1.05       0.92       1.18
  Hodgkin\'s disease                                                 7                       1.28       0.51       2.66      11      1.91       0.95       3.43      6       1.32       0.47       2.88      2       0.62       0.06       2.29      26       1.37       0.89       2.01
  NHL and other lymphohaematopoietic                                103                      1.11       0.91       1.35     102      1.02       0.83       1.24      72      1.01       0.79       1.27      52      1.18       0.88       1.55      329      1.07       0.96       1.19
  Multiple myeloma and other immunoproliferative                     61                      1.24       0.95       1.60      75    **1.43**   **1.13**   **1.80**    38      1.04       0.73       1.42      22      1.00       0.63       1.52      196    **1.22**   **1.06**   **1.41**
  Leukaemia                                                          84                      1.09       0.87       1.35      78      0.98       0.78       1.23      42      0.81       0.59       1.10      22      0.77       0.48       1.17      226      0.96       0.83       1.09
  All cancers combined                                              4090                     1.01       0.98       1.04     4613   **1.07**   **1.04**   **1.10**   3158   **1.04**   **1.00**   **1.08**   2085   **1.13**   **1.09**   **1.18**   13946   **1.05**   **1.04**   **1.07**

Abbreviations: CI=confidence interval; LCI=lower CI; NHL=non-Hodgkin\'s lymphoma; Obs=observed numbers of cancers; SIMD=Scottish Index of Multiple Deprivation; SIR=standardised incidence ratio; UCI=upper CI.

Indirectly standardised for age, sex, calendar period of follow-up, and deprivation (SIMD 2004).

Because of changes in classification and coding of bladder tumours over time, all bladder tumours (invasive, *in situ*, and uncertain behaviour) were included. Significant findings are shown in bold.

###### Obs, SIRs[a](#t3-fn2){ref-type="fn"}, and 95% CI, by time since hip operation

                                                    **Time since hip operation**                                                                                                                                                
  ------------------------------------------------ ------------------------------ ---------- ---------- ---------- ------ ---------- ---------- ---------- ------ ---------- ---------- ---------- ------ ---------- ---------- ----------
  Mouth, pharynx                                                 13                  0.67       0.36       1.15      58      0.89       0.68       1.15      43      0.90       0.65       1.21      24      0.87       0.56       1.30
  Oesophagus                                                     30                  0.85       0.57       1.22     115      0.92       0.76       1.11      76    **0.76**   **0.60**   **0.95**    56      0.91       0.68       1.18
  Stomach                                                        32                  0.79       0.54       1.12     120      0.86       0.71       1.02     101      0.93       0.76       1.13      51      0.79       0.59       1.04
  Lung                                                          158                **0.73**   **0.62**   **0.86**   600    **0.80**   **0.74**   **0.87**   434    **0.75**   **0.68**   **0.82**   305    **0.86**   **0.76**   **0.96**
  Bone                                                           1                   1.23       0.00       7.03      1       0.38       0.00       2.16      3       1.61       0.30       4.77      2       1.84       0.17       6.78
  Connective tissue                                              4                   1.06       0.28       2.74      15      1.14       0.63       1.88      13      1.25       0.66       2.14      5       0.76       0.24       1.79
  Melanoma of skin                                               31                  1.27       0.86       1.80     101      1.18       0.96       1.43      66      0.95       0.73       1.21      52      1.10       0.82       1.44
  Basal cell carcinoma of skin                                  234                  1.01       0.89       1.15     924    **1.11**   **1.04**   **1.18**   688      1.00       0.92       1.07     456      0.99       0.90       1.09
  Corpus uteri                                                   16                  0.74       0.42       1.21      66      0.91       0.70       1.16      60      1.12       0.85       1.44      38      1.21       0.85       1.66
  Prostate                                                      121                  1.17       0.97       1.40     405      1.09       0.98       1.20     312      1.03       0.92       1.15     195      1.06       0.92       1.22
  Bladder[b](#t3-fn3){ref-type="fn"}                             45                **0.64**   **0.47**   **0.86**   237      0.95       0.83       1.08     195      0.96       0.83       1.10      90    **0.69**   **0.56**   **0.85**
  Kidney                                                         25                  0.92       0.59       1.36     101      1.06       0.87       1.29      84      1.12       0.90       1.39      46      0.97       0.71       1.29
  Hodgkin\'s disease                                             3                   1.25       0.24       3.70      7       0.90       0.36       1.86      10      1.82       0.87       3.36      6       1.83       0.66       4.01
  NHL and other lymphohaematopoietic                             39                  1.13       0.80       1.54     125      1.04       0.86       1.24     104      1.10       0.90       1.34      61      1.05       0.80       1.34
  Multiple myeloma and other immunoproliferative                 20                  1.18       0.72       1.83      83    **1.37**   **1.09**   **1.70**    50      1.00       0.74       1.32      43      1.33       0.96       1.79
  Leukaemia                                                      27                  1.04       0.69       1.52      77      0.84       0.66       1.05      76      1.03       0.81       1.28      46      1.03       0.75       1.38
  All cancers combined                                          1440                 1.00       0.95       1.05     5618   **1.10**   **1.07**   **1.13**   4220     1.03       1.00       1.06     2668     1.02       0.99       1.06

Abbreviations: CI=confidence interval; LCI=lower CI; NHL=non-Hodgkin\'s lymphoma; Obs=observed numbers of cancers; SIMD=Scottish Index of Multiple Deprivation; SIR=standardised incidence ratio; UCI=upper CI.

Indirectly standardised for age, sex, calendar period of follow-up, and deprivation (SIMD 2004).

Because of changes in classification and coding of bladder tumours over time, all bladder tumours (invasive, *in situ*, and uncertain behaviour) were included. Significant findings are shown in bold.

###### Cancers investigated in the study, and their diagnostic codes according to the ninth (ICD-9) and tenth (ICD-10) revisions of the International Classification of Diseases

  **Cancer**                                                   **ICD-9**                  **ICD-10**
  ------------------------------------------------ --------------------------------- --------------------
  Mouth, pharynx                                             141, 143--149            C01--C06, C09--C14
  Oesophagus                                                      150                        C15
  Stomach                                                         151                        C16
  Lung                                                            162                      C33, C34
  Bone                                                            170                      C40, C41
  Connective tissue                                               171                      C47, C49
  Melanoma of skin                                                172                        C43
  Basal cell carcinoma of skin                             173, ICD-O M-809            C44, ICD-O M-809
  Corpus uteri                                                    182                        C54
  Prostate                                                        185                        C61
  Bladder\*                                            188, 233.7, 236.7, 239.4       C67, D09.0, D41.4
  Kidney                                                          189                      C64, C65
  Hodgkin\'s disease                                              201                        C81
  NHL and other lymphohaematopoietic                200, 202.0--202.3, 202.5--202.8     C82--C85, C96
  Multiple myeloma and other immunoproliferative                  203                      C88, C90
  Leukaemia                                                 202.4, 204--208                C91--C95
  All cancers combined                                         140--208                    C00--C96

\*Because of changes in classification and coding of bladder tumours over time, all bladder tumours (invasive, *in situ*, and uncertain behaviour) were included.
